A multicentre randomized double-blind placebo-controlled phase III study of the efficacy and safety of xeligekimab (GR1501) in patients with moderate-to-severe plaque psoriasis.
Lin CaiCongjun JiangGuoqiang ZhangHong FangJinyan WangYumei LiHui XuRong XiaoYangfeng DingKun HuangChunlei ZhangLitao ZhangBin ChenXinsuo DuanWeili PanGuangming HanRongyi ChenLunfei LiuShoumin ZhangJuan TaoXiaowen PangJianbin YuHuiping WangYi ZhaoChengxin LiXiaojing KangLanying QinXiaofang ZhuJuan SuShanshan LiChunjun YangWenli FengTiechi LeiShan JiangRuihua FangMao LinQianjin LuChunxing XuWei WangJianzhong ZhangPublished in: The British journal of dermatology (2024)
Xeligekimab showed high efficacy and was well tolerated in Chinese patients with moderate-to-severe plaque psoriasis.